PERSPECTIVE article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1533748
Teplizumab: A Promising Intervention for Delaying Type 1 Diabetes Progression
Provisionally accepted
- Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Type 1 diabetes (T1D) arises from an autoimmune attack on pancreatic beta cells, leading to a reliance on external insulin to maintain glucose levels. In recent years, research has increasingly focused on preventive strategies for individuals at high risk. A promising new intervention in this field is Teplizumab, the first approved disease-modifying therapy for T1D.Teplizumab is designed to delay progression to stage 3 T1D in adults and children aged 8 years and older who are diagnosed with stage 2 T1D.
Keywords: type 1 diabetes, Mechanism, Teplizumab, Immunotherapy, anti-CD3 antibody Type 1 diabetes, Anti-CD3 antibody
Received: 24 Nov 2024; Accepted: 27 Mar 2025.
Copyright: © 2025 SALEEM and KHAN. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: MUHAMMAD RIZWAN SALEEM, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.